Alligator Bioscience announces preliminary outcome in rights issue

On September 21, 2026 Alligator Bioscience AB ("Alligator Bioscience" or the "Company"), reported the preliminary outcome of the rights issue of units that was announced on 23 July 2026 (the "Rights Issue"). The preliminary outcome indicates that the Rights Issue has been subscribed to approximately 17.1 percent with and without exercise of unit rights, of which approximately 16.7 percent were subscribed for by exercise of unit rights and approximately 0.5 percent were subscribed for without exercise of unit rights. The preliminary outcome thus indicates that guarantee commitments will be utilized with approximately 29.7 percent of the Rights Issue. Based on the preliminary outcome, Alligator Bioscience will initially receive SEK 58.8 million from the Rights Issue before issue costs and repayment of bridge loans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The subscription period in the Rights Issue ended on 18 September 2026. The Rights Issue comprised a maximum of 3,140,534,240 units whereof each unit consists of two (2) ordinary shares, one (1) warrant series TO 15 and one (1) warrant series TO 16. The preliminary outcome indicates that subscriptions with and without exercise of unit rights amount to a total of 538,108,763 units, corresponding to approximately 17.1 percent of the Rights Issue. The Rights Issue is thus subscribed below the guaranteed level and guarantee commitments will need to be utilized with approximately 29.7 percent of the Rights Issue, corresponding to a total of 931,891,237 units.

The final outcome of the Rights Issue is expected to be announced on 22 September 2026.

Advisers
APREA Partners AB acts as financial adviser in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.

(Press release, Alligator Bioscience, SEP 21, 2026, View Source [SID1234670967])